| Budget Amount *help |
¥103,090,000 (Direct Cost: ¥79,300,000、Indirect Cost: ¥23,790,000)
Fiscal Year 2023: ¥20,150,000 (Direct Cost: ¥15,500,000、Indirect Cost: ¥4,650,000)
Fiscal Year 2022: ¥20,150,000 (Direct Cost: ¥15,500,000、Indirect Cost: ¥4,650,000)
Fiscal Year 2021: ¥20,150,000 (Direct Cost: ¥15,500,000、Indirect Cost: ¥4,650,000)
Fiscal Year 2020: ¥20,150,000 (Direct Cost: ¥15,500,000、Indirect Cost: ¥4,650,000)
Fiscal Year 2019: ¥22,490,000 (Direct Cost: ¥17,300,000、Indirect Cost: ¥5,190,000)
|
|---|
| Outline of Final Research Achievements |
This study aimed to construct a novel developmental engineering technology using common marmosets to understand the acquisition of pluripotency and early embryonic development. First, fertilized egg clones were produced and pups were obtained, which led to the development of marmoset somatic cell nuclear transfer technology. By examining inhibitor conditions, the blastocyst acquisition rate and embryo quality increased, and ES cells were successfully established. In the creation of chimeric embryos, ICM transfer conditions were found that resulted in stable attachment of the embryos to host cells. Furthermore, a pseudo-implantation embryo culture method for marmoset embryos was established, and it became clear that embryos can develop in vitro to Carnegie stage 6. We found that the embryonic developmental fate could be changed by this embryo culture method or that the adhesion ability of the embryo changed depending on the time of action using MEK inhibitors.
|
